HIV News and Research RSS Feed - HIV News and Research

ContraVir granted Type B meeting with FDA to discuss proposal for FV-100 Phase 3 trial

ContraVir granted Type B meeting with FDA to discuss proposal for FV-100 Phase 3 trial

ContraVir Pharmaceuticals, Inc., a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies, announced today that it has been granted a Type B meeting with the U.S. Food and Drug Administration (FDA) to discuss its proposal for the design of a Phase 3 trial of ContraVir's lead antiviral candidate, FV-100. [More]
Real-time RT-PCR TaqMan assay helps differentiate active pulmonary TB from LTBI

Real-time RT-PCR TaqMan assay helps differentiate active pulmonary TB from LTBI

One of the roadblocks to the eradication of tuberculosis (TB) is the difficulty in identifying patients with latent TB infections (LTBI). Neither the tuberculin skin test (TST) nor interferon-gamma release assays (IGRAs) are capable of distinguishing active from latent infection or predicting the chance of reactivation. [More]
CytRx reports positive interim results from aldoxorubicin Phase 2 trial for treatment of GBM

CytRx reports positive interim results from aldoxorubicin Phase 2 trial for treatment of GBM

CytRx Corporation, a biopharmaceutical research and development company specializing in oncology, today announced positive interim results from its ongoing Phase 2 clinical trial with aldoxorubicin for the treatment of unresectable glioblastoma multiforme (GBM), a deadly form of brain cancer. [More]
Janssen, Gilead to jointly develop darunavir-based, single-tablet regimen for HIV treatment

Janssen, Gilead to jointly develop darunavir-based, single-tablet regimen for HIV treatment

Janssen R&D Ireland announced today an amendment to its existing agreement with Gilead Sciences, Inc., initially established in 2011, for the development of a once daily, darunavir-based, single-tablet regimen (STR) for the treatment of people living with HIV. [More]
Medical researchers at Saint Louis University bring hope to those in pain and sickness

Medical researchers at Saint Louis University bring hope to those in pain and sickness

This year, Saint Louis University medical researchers advanced their fields, contributing to human knowledge and bringing hope to those in pain and sickness. [More]
Cell-associated HIV transmission contributes to HIV epidemic

Cell-associated HIV transmission contributes to HIV epidemic

Dr. Deborah Anderson from Boston University School of Medicine (BUSM) and her colleagues are challenging dogma about the transmission of the human immunodeficiency virus type 1 (HIV-1). [More]
Higher parental education can increase depression risk in black youth

Higher parental education can increase depression risk in black youth

An investigation into factors related to disparities of depression in young adults has found that higher parental education - which has a protective effect for white youth - can also increase the risk of depression for black youth. [More]
FDA approves AbbVie's VIEKIRA PAK for treatment of patients with GT1 HCV infection

FDA approves AbbVie's VIEKIRA PAK for treatment of patients with GT1 HCV infection

The U.S. Food and Drug Administration has approved AbbVie's VIEKIRA PAK, an all-oral, interferon-free treatment, with or without ribavirin (RBV), for the treatment of patients with chronic genotype 1 (GT1) hepatitis C virus (HCV) infection, including those with compensated cirrhosis. [More]
SLU investigators find promising candidates for new herpes virus treatments

SLU investigators find promising candidates for new herpes virus treatments

Saint Louis University research findings published in the December issue of Antimicrobial Agents and Chemotherapy report a family of molecules known as nucleotidyltransferase superfamily (NTS) enzyme inhibitors are promising candidates for new herpes virus treatments. [More]
Certain complementary medicines may cause side effects, warns NPS MedicineWise

Certain complementary medicines may cause side effects, warns NPS MedicineWise

With new information from Melbourne’s Peter MacCallum Cancer Centre revealing that some complementary medicines can interact with cancer treatment, NPS MedicineWise reminds all Australians that complementary medicines can cause side effects, and interact with other over-the-counter and prescription medicines. [More]
Kaiser Permanente study: Self-reported exercise lowers blood pressure, blood glucose levels

Kaiser Permanente study: Self-reported exercise lowers blood pressure, blood glucose levels

Self-reported moderate to vigorous exercise was associated with lower blood pressure and blood glucose levels in a Kaiser Permanente study published in the journal Preventing Chronic Disease. [More]
Chimerix, ContraVir collaborate to develop and commercialize antiviral drug candidate CMX157

Chimerix, ContraVir collaborate to develop and commercialize antiviral drug candidate CMX157

Chimerix, Inc., a biopharmaceutical company developing novel, oral antivirals in areas of high unmet medical need, and ContraVir Pharmaceuticals, Inc., a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies, announced today that the companies have entered into a strategic collaboration for the further clinical development and commercialization of CMX157. [More]
Inovio begins hTERT DNA immunotherapy trial in adults with breast, lung and pancreatic cancer

Inovio begins hTERT DNA immunotherapy trial in adults with breast, lung and pancreatic cancer

Inovio Pharmaceuticals, Inc. announced it has initiated a phase I trial of its hTERT DNA immunotherapy (INO-1400) alone or in combination with Inovio's IL-12 immune activator (INO-9012) in adults with breast, lung, or pancreatic cancer at high risk of relapse after surgery and other cancer treatments. [More]
Research findings may lead to new treatment strategies for Ewing sarcoma

Research findings may lead to new treatment strategies for Ewing sarcoma

The genetic abnormality that drives the bone cancer Ewing sarcoma operates through two distinct processes - both activating genes that stimulate tumor growth and suppressing those that should keep cancer from developing. These findings by Massachusetts General Hospital investigators, published in the November issue of Cancer Cell, may lead to new therapies targeting these aberrant mechanisms. [More]
Research outlines new model for measuring acceptability of contraceptive vaginal ring

Research outlines new model for measuring acceptability of contraceptive vaginal ring

The Population Council published new research in the November issue of the journal Contraception demonstrating that an investigational one-year contraceptive vaginal ring containing Nestorone and ethinyl estradiol was found to be highly acceptable among women enrolled in a Phase 3 clinical trial. [More]
Researchers identify a single protein as root cause of multiple allergic reactions

Researchers identify a single protein as root cause of multiple allergic reactions

Johns Hopkins and University of Alberta researchers have identified a single protein as the root of painful and dangerous allergic reactions to a range of medications and other substances. If a new drug can be found that targets the problematic protein, they say, it could help smooth treatment for patients with conditions ranging from prostate cancer to diabetes to HIV [More]
Researchers find new 'sliding scale' model to rule out blood clots in lungs

Researchers find new 'sliding scale' model to rule out blood clots in lungs

Researchers from Intermountain Medical Center in Salt Lake City have identified a new "sliding scale" model used to rule out potentially deadly blood clots in the lungs, known as pulmonary embolisms, that is more accurate than current diagnostic methods. [More]
EGPAF to receive $63 million UNITAID grant to improve early infant diagnosis of HIV programs

EGPAF to receive $63 million UNITAID grant to improve early infant diagnosis of HIV programs

The Elizabeth Glaser Pediatric AIDS Foundation is pleased to announce that it has been selected by the UNITAID Executive Board to receive up to $63 million in funding to improve early infant diagnosis (EID) of HIV programs in nine African countries. This investment will pave the way for universal access to HIV testing and enable a ten-fold increase in HIV treatment, thus transforming the effort to end AIDS in children worldwide. [More]

New intervention combines social media with behavioral psychology to encourage more HIV testing

Social media such as Twitter and Facebook can be valuable in the fight against HIV in the United States, where research has demonstrated they can prompt high-risk populations to request at-home testing kits for the virus that causes AIDS, suggesting a way to potentially boost testing rates. [More]
Researchers explore lifespan variability between races

Researchers explore lifespan variability between races

Eliminating health disparities between races is a goal of many groups and organizations, but a team of sociologists suggests that finding the reasons for the differences in the timing of black and white deaths may be trickier than once thought. [More]